Avenue Therapeutics, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Cover
- Document And Entity Information
Financial Statements
Notes to Financial Statements
Accounting Policies
- Significant Accounting Policies (Policies)
Notes Tables
Notes Details

Organization, Plan of Business Operations (Details Textual)

v3.19.1

Organization, Plan of Business Operations (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Feb. 08, 2019	Dec. 31, 2018	Nov. 12, 2018	Dec. 31, 2017
Retained Earnings (Accumulated Deficit)		$ (42,209)		$ (20,661)
Invagen Pharmaceuticals Inc [Member]
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned			$ 215,000
Invagen Pharmaceuticals Inc [Member] \| Common Stock [Member]
Stock Issued During Period, Value, Acquisitions	$ 180,000
Subsequent Event [Member] \| Line of Credit [Member]
Initial Financing Amount	3,000
Interim Financing Amount	$ 7,000
Subsequent Event [Member] \| Invagen Pharmaceuticals Inc [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	5,833,333
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned	$ 31,500
Business Acquisition, Share Price	$ 6.00
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners	33.30%

- Definition

Amount of initial financing receivable.

+ References

No definition available.

+ Details

Name:	atxi_InitialFinancingAmount
Namespace Prefix:	atxi_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of interim financing receivable.

+ References

No definition available.

+ Details

Name:	atxi_InterimFinancingAmount
Namespace Prefix:	atxi_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

+ Details

Name:	us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Number of shares of equity interests issued or issuable to acquire entity.

+ References

+ Details

Name:	us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.

+ References

No definition available.

+ Details

Name:	us-gaap_BusinessAcquisitionSharePrice
Namespace Prefix:	us-gaap_
Data Type:	num:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.

+ References

No definition available.

+ Details

Name:	us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

+ Details

Name:	us-gaap_RetainedEarningsAccumulatedDeficit
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Value of stock issued pursuant to acquisitions during the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_StockIssuedDuringPeriodValueAcquisitions
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	srt_OwnershipAxis=atxi_InvagenPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: